Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Treasury Shares (2016 - 2025)

UroGen Pharma (URGN) has disclosed Treasury Shares for 10 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 27.83% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, up 27.83%, and an annual FY2025 reading of $1.9 million, up 27.83% over the prior year.
  • Treasury Shares was $1.9 million for Q4 2025 at UroGen Pharma, up from $1.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.9 million in Q4 2025 and bottomed at $690955.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Treasury Shares fell 8.27% in 2022, then soared 59.01% in 2023.
  • Year by year, Treasury Shares stood at $753274.0 in 2021, then dropped by 8.27% to $690955.0 in 2022, then soared by 59.01% to $1.1 million in 2023, then skyrocketed by 37.24% to $1.5 million in 2024, then grew by 27.83% to $1.9 million in 2025.
  • Business Quant data shows Treasury Shares for URGN at $1.9 million in Q4 2025, $1.5 million in Q4 2024, and $1.1 million in Q4 2023.